Cassava Sciences Announces Results From Cognition Maintenance Study Showing Simufilam Slowed Cognitive Decline By 38% Versus Placebo Over 6 months In Patients With Mild-To-Moderate Alzheimer's Disease
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences has announced that its cognition maintenance study showed that Simufilam slowed cognitive decline by 38% versus placebo over 6 months in patients with mild-to-moderate Alzheimer's disease.
July 05, 2023 | 1:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cassava Sciences' Simufilam has shown promising results in slowing cognitive decline in Alzheimer's patients, which could potentially boost the company's stock.
The positive results from the cognition maintenance study of Simufilam indicate a potential breakthrough in Alzheimer's treatment. This could lead to increased demand for the drug, resulting in higher revenues for Cassava Sciences and a potential increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100